Neither atezolizumab plus chemotherapy nor atezolizumab alone improved overall survival when compared to chemotherapy alone in patients with advanced urothelial cancer in the phase 3 IMvigor130 trial. Neither atezolizumab plus chemotherapy nor atezolizumab alone improved OS when compared to chemotherapy alone in patients with advanced urothelial cancer.
Neither atezolizumab plus chemotherapy nor atezolizumab alone improved overall survival when compared to chemotherapy alone in patients with advanced urothelial cancer in the phase 3 IMvigor130 trial. Neither atezolizumab plus chemotherapy nor atezolizumab alone improved OS when compared to chemotherapy alone in patients with advanced urothelial cancer.
Neither atezolizumab plus chemotherapy nor atezolizumab alone improved overall survival when compared to chemotherapy alone in patients with advanced urothelial cancer in the phase 3 IMvigor130 trial. Neither atezolizumab plus chemotherapy nor atezolizumab alone improved OS when compared to chemotherapy alone in patients with advanced urothelial cancer.
Updated results from the KATHERINE trial suggest that T-DM1 can improve OS when compared to trastuzumab in patients with HER2+ early breast cancer who have residual invasive disease after neoadjuvant therapy. T-DM1 can improve OS when compared to trastuzumab in patients with HER2+ early breast cancer who have residual invasive disease after neoadjuvant therapy.
Completion of the Phase 1 EPI-7386 combination study with Xtandi® (enzalutamide) expected in the third calendar quarter of 2023 followed by initiation of the.